Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lenvatinib: Phase Ib/II data

Data from 78 evaluable patients with stage IV melanoma in the modified intent-to-treat (mITT) population of the Phase II portion of a Phase Ib/II trial showed that 20 mg oral lenvatinib

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE